US 11,690,847 B2
Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
Sanford Markowitz, Pepper Pike, OH (US); Won Jin Ho, Cleveland, OH (US); Stephen P. Fink, Avon Lake, OH (US); and Vinay Varadan, Westlake, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Appl. No. 16/465,500
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
PCT Filed Nov. 30, 2017, PCT No. PCT/US2017/063959
§ 371(c)(1), (2) Date May 30, 2019,
PCT Pub. No. WO2018/102552, PCT Pub. Date Jun. 7, 2018.
Claims priority of provisional application 62/510,166, filed on May 23, 2017.
Claims priority of provisional application 62/428,259, filed on Nov. 30, 2016.
Prior Publication US 2020/0061073 A1, Feb. 27, 2020
Int. Cl. A61K 31/5377 (2006.01); A61P 1/00 (2006.01); A61K 31/421 (2006.01); A61K 31/426 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); A61K 31/56 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/421 (2013.01); A61K 31/426 (2013.01); A61K 31/437 (2013.01); A61K 31/4365 (2013.01); A61K 31/4439 (2013.01); A61K 31/4985 (2013.01); A61K 31/519 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61P 1/00 (2018.01)] 6 Claims
 
1. A method of treating intestinal, gastrointestinal, or bowel disorders in a subject in need thereof, the method comprising administering to the subject therapeutically effective amounts of a 15-PGDH inhibitor of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
and a corticosteroid, dexamethasone.